- Siri Panduan Infografik Berkaitan Tuntutan Mata CPD
- Permohonan Pendaftaran Sementara Ahli Farmasi dengan Lembaga Farmasi Malaysia
- SOALAN-SOALAN LAZIM (FAQ) BERKAITAN TUNTUTAN MATA CPD PROGRAM PERKHIDMATAN FARMASI
- Pesanan Untuk Ahli Farmasi Berdaftar
- Senarai Premis Latihan Bagi Pegawai Farmasi Provisional (PRP)
Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 931 | Linezolid 20mg/ml Suspension | J01XX08-000-L80-01-XX | A* | MRSA patients with severe sepsis requiring intensive care and not clinically responding to vancomycin | None | CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily |
| 932 | Linezolid 2mg/ml Injection | J01XX08-000-P30-01-XXX | A* | MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycin | None | ADULT: 600 mg twice daily for 10 - 14 days. CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily |
| 933 | Linezolid 600mg Tablet | J01XX08-000-T10-01-XXX | A* | MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycin. | None | ADULT: Above 12 years 600 mg every 12 hours for 10-14 days. CHILD :10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily |
| 934 | Liquid Paraffin | A06AA01-000-L50-01-XX | C | Constipation | None | ADULT: 10-30 ml daily at night. CHILD: not recommended. |
| 935 | Lithium Carbonate 300mg Tablet | N05AN01121T1001XX | A | i) Prophylaxis and treatment of acute mania and hypomania episodes ii)Prophylaxis of manic depression in bipolar illness or bipolar depression and recurrent depression | Dose depends on the preparation used. Doses should be adjusted to produce a serum-lithium concentration of 0.4-1 mmol/l. | |
| 936 | Loperamide 2mg Capsule | A07DA03-110-C10-01-XX | B | i. Adjunct to rehydration in: a. acute diarrhea in adult; and b. chronic diarrhea in adult ii. In patients with an ileostomy, it can be used to reduce the number and volume of stools and to harden their consistency | None | 6 – 8 mg per day up to max. of 16mg per day Dosing is individualised and according to product insert / protocol |
| 937 | Lopinavir 100mg and Ritonavir 25mg Tablet | J05AE06-964-T10-02-XXX | A | Second line treatment for HAART regimen in combination with other anti-retroviral agents | None | Adult: - Therapy-naive patients: 400/100 mg bd or 800/200 mg once daily; - Therapy-experienced patients: 400/100 mg bd. - Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose. |
| 938 | Lopinavir 200 mg and Ritonavir 50 mg Tablet | J05AE06-964-T10-01-XXX | A | Second line treatment for HAART regimen in combination with other anti-retroviral agents | None | Adult: - Therapy-naive patients: 400/100 mg bd or 800/200 mg once daily; - Therapy-experienced patients: 400/100 mg bd. - Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose. |
| 939 | Lopinavir 80mg & Ritonavir 20mg (per ml) Oral Solution | J05AE06-964-L99-01-XXX | A | Management of patients with asymptomatic and symptomatic (early or advanced) HIV Infection with CD4 cell counts <50 cubic mm | None | Tab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg once daily. Therapy-experienced patients 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Can be used w/ no dose adjustment. Childn >40 kg or w/ BSA >1.4 m2 Adult dose. Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15 kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg. |
| 940 | Loratadine 10mg Tablet | R06AX13-000-T10-01-XXX | B | Allergic rhinitis and allergic dermatoses | None | ADULT and CHILD over 6 years 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily |
| 941 | Loratadine 1mg/ml Syrup | R06AX13-000-L90-01-XXX | B | Allergic rhinitis, chronic urticaria and other allergic dermatological disorders | None | ADULT and CHILD over 6 years : 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily |
| 942 | Loratadine 5mg and Pseudoephedrine Sulphate 120mg Tablet | R01BA52-988-T10-01-XXX | A/KK | For treatment of allergic rhinitis and allergic dermatoses | None | ADULT and CHILD over 12 years 1 tablet twice daily |
| 943 | Lorazepam 1mg Tablet | N05BA06-000-T10-01-XXX | A/KK | i) Severe anxiety ii) Insomnia | None | i) 1 - 4 mg increase to 10 mg daily in divided doses. ELDERLY (or delibitated) half adult dose ii) 1 - 2 mg at bedtime Not recommended in children |
| 944 | Lorlatinib 100mg Film-Coated Tablet | L01ED05-000-T32-02-XXX | A* | As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). | To be prescribed by Oncologist only | 100 mg taken orally once daily. Continue treatment as long as the patient is deriving clinical benefit from therapy |
| 945 | Lorlatinib 25mg Film-Coated Tablet | L01ED05-000-T32-01-XXX | A* | As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). | To be prescribed by Oncologist only | 100 mg taken orally once daily. Continue treatment as long as the patient is deriving clinical benefit from therapy |
| 946 | Losartan 100 mg Tablet | C09CA01-500-T10-02-XXX | B | Patients intolerant to ACE inhibitors in: i) Hypertensive patient with left ventricular hypertrophy ii) Type 2 Diabetes Mellitus with chronic kidney disease iii) Hypertension | - | i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing is individualised and according to product insert / protocol. |
| 947 | Losartan 100mg & Hydrochlorothiazide 25mg Tablet | C09DA01-935-T10-04-XXX | A* | i) Hypertension in patients intolerant to ACE inhibitors ii) Hypertensive patient with left ventricular hypertrophy | None | i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing is individualised and according to product insert / protocol. |
| 948 | Losartan 100mg and Hydrochlorothiazide 12.5mg Tablet | C09DA01-935-T10-03-XXX | A* | i) Hypertension in patients intolerant to ACE inhibitors ii) Hypertensive patient with left ventricular hypertrophy | None | i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing is individualised and according to product insert / protocol. |
| 949 | Losartan 50mg and Hydrochlorothiazide 12.5mg Tablet | C09DA01-935-T10-01-XXX | A/KK | i) Hypertension in patients intolerant to ACE inhibitors ii) Hypertensive patient with left ventricular hypertrophy | None | i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing is individualised and according to product insert / protocol. |
| 950 | Losartan 50mg Tablet | C09CA01-500-T10-01-XXX | B | Patients intolerant to ACE inhibitors in: i) Hypertensive patient with left ventricular hypertrophy ii) Type 2 Diabetes Mellitus with chronic kidney disease iii) Hypertension | - | i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing is individualised and according to product insert / protocol. |
| 951 | Macitentan 10mg Film-coated Tablet | C02KX04-000-T32-01-XXX | A* | As monotherapy or combination for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. | To be prescribed by PAH-trained Respiratory Physician and Cardiologist only. | Recommended daily dose macitentan is 10mg (1 tablet), with or without food. The film-coated tablets are not breakable and must be swallowed whole with water. |
| 952 | Magnesium Sulphate 45% Paste | D11AX05-183-G60-01-XXX | C | Inflammatory skin conditions such as boils and carbuncles | None | Apply under dressing |
| 953 | Magnesium Sulphate 50% Injection | B05XA05-183-P30-01-XXX | C | i)Treatment and prophylaxis of acute hypomagnesaemia ii) Prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia) | None | i)Mild hypomagnesemia (ADULT): 1gm magnesium sulphate (8mEq) IM every 6 hours for 4 doses. Severe hypomagnesemia (ADULT): 0.25 g/kg IM over 4 hours. Alternative dose of 5g may be given by slow intravenous infusion over 3 hours ii) Toxemia of pregnancy: An initial intravenous dose of 4gm of magnesium sulphate is recommended. Followed by an intramuscular dose of 4-5gm into each buttock. This may be followed by a dose of 4-5gm into alternate buttocks every 4 hours as needed. Alternatively, the initial dose IV dose may be followed by an infusion of 1-2gm/hr |
| 954 | Magnesium Trisilicate Mixture | A02AA10-912-L21-01-XXX | C | Heartburn, dyspepsia | None | ADULT children over 12 years: 10-20ml 3 times daily or as required; CHILD: 5-11 years: 5-10 ml three times a day or as required |
| 955 | Magnesium Trisilicate Tablet | A02AA10-912-T10-01-XXX | C | Heartburn, dyspepsia | - | ADULT 1-2 tablet to be chewed up to 6 times a day before meals. CHILD over 6 years one tablet to be taken 3-4 times a day |
| 956 | Magnesium, Aluminium Hydroxide and Simethicone Suspension | V07AB00-900-L80-01-XXX | C | For the relief from gastric acidity, indigestion, heartburn, flatulence and dyspepsia. | - | 5 to 10ml as required or one hour after food and at bedtime |
| 957 | Malathion 1% Shampoo | P03AX03-000-L52-01-XXX | C+ | Lice infestation | - | Wet hair, apply shampoo and work up lather. Leave for 15 minutes and rinse, comb. Repeat if necessary after 7 - 9 days |
| 958 | Mannitol 10% Injection (10 g/100 ml) | B05BC01-000-P30-01-XXX | A | Cerebral oedema | 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age | |
| 959 | Mannitol 20% Injection (20 g/100 ml) | B05BC01-000-P30-02-XXX | A | Cerebral oedema | - | 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age |
| 960 | Measles and Rubella Virus Live, Attenuated Vaccine Injection | J07BD52-963-P40-02-XXX | C+ | Immunisation against measles and rubella. | - | 0.5ml by deep SC injection. Dosing is according to Immunisation Schedule under NIP and product insert. |